Do you want to read an article? Please log in or register.
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study
Inflammatory Bowel Disease
Indications
Related content
Inflammatory Bowel Disease
Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
Inflamm Bowel Dis
Ünal NG, Bakkaloğlu OK, Kav T, Eşkazan T, Kani HT, Akpınar A, Akıncıoğlu P, Dağcı G, Şendur İ, Büyüktorun İ, Barutçu S, Kılıç G, Bengi G, Çavuş B, Oruç N, Alahdab YÖ, Atuğ Ö, Dinçer D, Karakan T, Hatemi Aİ, Erzin YZ, Tezel A, Törüner M, Akyüz F, Çelik AF
doi: 10.1093/ibd/izag126
Inflammatory Bowel Disease
Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study
J Crohns Colitis
D'Amico F, Fanizzi F, Dal Buono A, Gabbiadini R, Nardone OM, Zilli A, Allocca M, Lauriola GM, Jairath V, Peyrin-Biroulet L, Fiorino G, Castiglione F, Massimino L, Mastronardi M, Armuzzi A, Danese S
doi: 10.1093/ecco-jcc/jjag062
Inflammatory Bowel Disease
Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study)
Inflamm Bowel Dis
Lin SH, Kuo CJ, Chuang CH, Chang CW, Chung CS, Chou JW, Huang TY, Yen HH, Tsai TJ, Lin CP, Chang CH, Tai CM, Tai WC, Yao CC, Chen CC, Pan YB, Le PH
doi: 10.1093/ibd/izag150
Inflammatory Bowel DiseaseFurther Publications
Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry
United European Gastroenterol J
Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, Mujagic Z, Pierik M, Verleye LMM, Duijvestein M, Bouwknegt DG, Visschedijk MC, Srivastava N, West RL, Oldenburg B, Löwenberg M, van Schaik FDM, Dutch ICC Registry
doi: 10.1002/ueg2.70141
Inflammatory Bowel Disease
Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study
Clin Gastroenterol Hepatol
Camões Neves J, Costa D, Cristiano M, Portela F, Fernandes AR, Fernandes S, Gonçalves N, Paulo JP, Portugal M, Gututui M, Fernandes D, Costa C, Madureira AM, Marques J, Conde PV, Damasceno J, Guimarães A, Rebelo A, Gonçalves M, Soares J, Mendes SS, Arroja B, Gonçalves R, Leal T, GEDII (Portuguese IBD Group)
doi: 10.1016/j.cgh.2026.07.020
Inflammatory Bowel Disease
Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study
Inflamm Bowel Dis
Boute EH, Gianolio L, Mahmmod S, Pochesci S, Armstrong K, Henderson P, Wilson DC, de Ridder L, Russell RK, Escher JC
doi: 10.1093/ibd/izaf335
Inflammatory Bowel Disease
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID
United European Gastroenterol J
Calméjane L, Reenaers C, Gay C, Amiot A, Nuzzo A, Vuitton L, Atanasiu C, Stefanescu C, Altwegg R, Guillo L, Serrero M, Bouguen G, Nachury M, Cosquer GL, Roblin X, Abitbol V, Hammoudi N, Simon M, Fumery M, Savoye G, Benezech A, Cavicchi M, Charkaoui M, Buisson A, Caron B, Coffin B, Geyl S, Goutorbe F, Hupé M, Vidon M, Laharie D, Kirchgesner J, Uzzan M, GETAID‐AFTER‐VEDO Study Group
doi: 10.1002/ueg2.70203
Inflammatory Bowel Disease
Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study
J Crohns Colitis
Privitera G, Bezzio C, Buono AD, Gabbiadini R, Loy L, Ranucci L, Bertin L, Masoni B, Migliorisi G, Sauta E, Delleani M, Savevski V, Porta MD, D'amico S, Armuzzi A
doi: 10.1093/ecco-jcc/jjaf239
Inflammatory Bowel Disease
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry
United European Gastroenterol J
Iborra M, Botella B, Martín-Arranz MD, Ceballos D, Martínez-Pascual C, Garrido A, Varela P, Moreta M, Brunet-Mas E, González-Lama Y, Rodríguez-González E, Vicuña M, Gisbert JP, Ordás I, Argüelles-Arias F, Tosca-Cuquerella J, Vicente-Lidón R, Sierra-Ausín M, Rodríguez-Lago I, Martín-Rodríguez D, Paredes JM, Sicilia B, García de la Filia I, Jiménez N, Barreiro-de Acosta M, Betoré E, Ferrer-Bradley I, García-Alles L, Huguet JM, Castellet-Farrús S, García MJ, Gutiérrez-Casbas A, Ponferrada-Díaz Á, Ramos L, Calafat M, Vera I, Suárez-Ferrer C, Fernández-Velado E, Rodríguez-Sánchez S, Mínguez A, Mancebo A, Barrio J, Lario S, de La Cruz DR, Hernández-Camba A, Rodríguez-Gutiérrez C, Chaparro M, Ricart E, Almenara-Michelena L, Balaguer A, Domènech E, Nos P
doi: 10.1002/ueg2.70223